Estimating the burden of disease attributable to injecting drug use as a risk factor for HIV, hepatitis C, and hepatitis B: findings from the Global Burden of Disease Study 2013

[Diffusé le 11-10-2016]

Source : The Lancet Infectious Diseases 2016; 16(12): 1385-98

Degenhardt, Louisa; Charlson, Fiona; Stanaway, Jeff; Larney, Sarah; Alexander, Lily T; Hickman, Matthew; Cowie, Benjamin; Hall, Wayne D; Strang, John; Whiteford, Harvey; Vos, Theo.

Evaluation du risque d’infection au VIH, VHC et VHB, imputable à l'injection de drogues: conclusions de l’étude 'Global Burden of Disease Study 2013'

Article commenté par : L'équipe éditoriale AddictoScope

Cette étude, commandée par la Fondation Bill & Melinda Gates, montre que l’injection de drogue est l’un principaux risque imputable à ces infections virales. La mortalité liée à l'hépatite C faisant suite à une pratique d’injection représente une problématique importante pour les pays à haut-revenus. La mise en place à l’échelle nationale de stratégies efficaces de préventions (amélioration de la couverture territoriale des programmes d’échange de seringue et de l’accès aux traitements de substitution opiacés) et curatives (diagnostique et accès aux nouveaux traitements antirétroviraux), permettront de réduire significativement les décès liés à ces infections.

Summary

Background Previous estimates of the burden of HIV, hepatitis B virus (HBV), and hepatitis C virus (HCV) among people who inject drugs have not included estimates of the burden attributable to the consequences of past injecting. We aimed to provide these estimates as part of the Global Burden of Disease (GBD) Study 2013.
Methods We modelled the burden of HBV and HCV (including cirrhosis and liver cancer burden) and HIV at the country, regional, and global level. We extracted United Nations data on the proportion of notified HIV cases by transmission route, and estimated the contribution of injecting drug use (IDU) to HBV and HCV disease burden by use of a cohort method that recalibrated individuals' history of IDU, and accumulated risk of HBV and HCV due to IDU. We estimated data on current IDU from a meta-analysis of HBV and HCV incidence among injecting drug users and country-level data on the incidence of HBV and HCV between 1990 and 2013. We calculated estimates of burden of disease through years of life lost (YLL), years of life lived with disability (YLD), deaths, and disability-adjusted life-years (DALYs), with 95% uncertainty intervals (UIs) calculated for each metric.
Findings In 2013, an estimated 10·08 million DALYs were attributable to previous exposure to HIV, HBV, and HCV via IDU, a four-times increase since 1990. In total in 2013, IDU was estimated to cause 4·0% (2·82 million DALYs, 95% UI 2·4 million to 3·8 million) of DALYs due to HIV, 1·1% (216 000, 101 000–338 000) of DALYs due to HBV, and 39·1% (7·05 million, 5·88 million to 8·15 million) of DALYs due to HCV. IDU-attributable HIV burden was highest in low-to-middle-income countries, and IDU-attributable HCV burden was highest in high-income countries.
Interpretation IDU is a major contributor to the global burden of disease. Effective interventions to prevent and treat these important causes of health burden need to be scaled up.
Funding Bill & Melinda Gates Foundation and Australian National Health and Medical Research Council.


Podcast Series - Sous Emprise
Noter cet article :

Ma bibliographie

Accédez à vos articles favoris, classez-les par dossiers ou encore exportez-les sous format ENDNOTE !


Rechercher

Besoin d'aide ?
Recherche avancée
Recherche par revues
798 articles actuellement disponibles
A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Y | Z | 0-9
Recherche par rubriques